Alejandro R. Marrero-Gonzalez

Alejandro R. Marrero-Gonzalez

Auto-generated profile, based on publicly available information

Alejandro R. Marrero-Gonzalez

Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
AMAlejandro R. Marrero-Gonzalez
Alejandro R. Marrero-Gonzalez
TDTanner J. Diemer
Tanner J. Diemer
SNShaun A. Nguyen
Shaun A. Nguyen
TCTerence J. M. Camilon
Terence J. M. Camilon
KMKirsten Meenan
Kirsten Meenan
AOAshli O’rOurke
Ashli O’rOurke
Objective: The objective of this systematic review and meta-analysis was to evaluate the diagnostic accuracy of AI-assisted technologies, including endoscopy, voice analysis, and histopathology, for detecting and classifying laryngeal lesions. Methods: A systematic search was conducted in PubMed, Embase, etc. for studies utilizing voice analysis, histopathology for laryngeal lesions, or AI-assisted endoscopy. The results of diagnostic accuracy, sensitivity and specificity were synthesized by a meta-analysis. Results: 12 studies employing AI-assisted endoscopy, 2 studies for voice analysis, and 4 studies for histopathology were included in the meta-analysis. The combined sensitivity of AI-assisted endoscopy was 91% (95% CI 87–94%) for the classification of benign from malignant lesions and 91% (95% CI 90–93%) for lesion detection. The highest accuracy pooled in detecting lesions versus healthy tissue was the AI-aided endoscopy was 94% (95% CI 92–97%). Conclusions: For laryngeal lesions, AI-assisted endoscopy shows excellent diagnosis accuracy. But more sizable prospective trials are needed to confirm the practical clinical value.

9 August 2024 in The Laryngoscope
Verified
Journal Article
Closed access
ABAkash M. Bhat
Akash M. Bhat
AMAlejandro R. Marrero‐Gonzalez
Alejandro R. Marrero‐Gonzalez
SNShaun A. Nguyen
Shaun A. Nguyen
MSMegan Scharner
Megan Scharner
KMKirsten Meenan
Kirsten Meenan
RSRobert T. Sataloff
Robert T. Sataloff

7 August 2024 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
AMAlejandro R. Marrero-Gonzalez
Alejandro R. Marrero-Gonzalez
CWCeline Ward
Celine Ward
SNShaun A. Nguyen
Shaun A. Nguyen
SJSeth S. Jeong
Seth S. Jeong
HRHabib G. Rizk
Habib G. Rizk
Purpose: To determine factors associated with steroid responsiveness and efficacy of biologic disease-modifying anti-rheumatic (DMARD) use in patients with Cogan Syndrome (CS). Methods: A systematic search of Cochrane Library, PubMed, CINAHL, and Scopus was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Any study describing audiometric or vestibular data and pharmacologic treatment in patients with CS was included. Due to limited literature, only case reports/case series were included. Results: Seventy case reports or case series studies comprising 79 individual cases of CS were included. A difference in vestibular symptoms with a higher prevalence in the steroid-resistant group than the steroid-responsive group was found (79.5% vs 57.9%, p = 0.04). Eighteen (60.0%) patients treated only with oral steroids had no audiological improvement, while twelve (n = 12; 85.7%) patients treated with biologic DMARD showed audiological improvement. The steroid-responsive group had an overall better response to DMARDs than the steroid-resistant group (62.1% vs 45.0%; 100.0% vs 77.8%). Conclusions: Our study synthesized the available literature to better characterize steroid resistance in patients with Cogan syndrome and treatment outcomes. Vestibular symptoms were noted to be more prevalent in patients who were eventually labeled as steroid resistant. There were higher rates of audiological improvement in patients given biologic DMARDs rather than conventional DMARDs or steroids only. Further studies are needed to characterize each individual vestibular symptom and investigate the utility and timing of biologic DMARDs in managing patients with Cogan syndrome.

10 May 2024 in The Laryngoscope
Verified
Journal Article
Closed access
LHLuke D. Heiland
Luke D. Heiland
AMAlejandro R. Marrero‐Gonzalez
Alejandro R. Marrero‐Gonzalez
SNShaun A. Nguyen
Shaun A. Nguyen
HFHannah G. Farmer
Hannah G. Farmer
VRVinay K. Rathi
Vinay K. Rathi
RSRodney J. Schlosser
Rodney J. Schlosser

5 January 2025 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
AMAlejandro R. Marrero‐Gonzalez
Alejandro R. Marrero‐Gonzalez
DNDouglas P. Nanu
Douglas P. Nanu
SNShaun A. Nguyen
Shaun A. Nguyen
EBEmily Brennan
Emily Brennan
WAWilliam Greer Albergotti
William Greer Albergotti
EGEvan Graboyes
Evan Graboyes

17 May 2025 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Open access
PDF file
BKBrian A. Keith
Brian A. Keith
AMAlejandro R. Marrero-Gonzalez
Alejandro R. Marrero-Gonzalez
ICIsabelle J. Chau
Isabelle J. Chau
SNShaun A. Nguyen
Shaun A. Nguyen
WAWilliam G. Albergotti
William G. Albergotti
JNJason Newman
Jason Newman
Purpose: Obtaining negative margins in primary tumor resection is essential to decreasing recurrence and mortality. Fluorescence imaging may aid in complete tumor removal. As fluorescent agents are still under clinical trial investigation for use in head and neck cancer (HNC), their effectiveness in intraoperative margin assessment (IMA) remains unclear. This scoping review examines the use of fluorescent-guided surgery (FGS) in the treatment of HNC, highlighting significant opportunities in this nascent field. Methods: PubMed, Scopus, CINAHL, and Cochrane Library were searched from inception through March 22, 2024. This study was conducted under PRISMA-ScR guidelines. Data on study characteristics, fluorescence and imaging techniques, imaging efficacy, and diagnostic accuracy were extracted. Results: Twenty-seven prospective studies from 2013 to 2024 on intraoperative FGS in HNC, involving 455 patients from six countries, were included. Studies ranged from preclinical to phase II trials, applying various fluorescent techniques, predominantly indocyanine green and IRDye800CW, to enhance surgical precision. Imaging assessments were conducted in-vivo, ex-vivo, or both, using a wide range of devices and taking an additional 0 to 30 min intraoperatively. Quantitative measures like signal-to-background ratio and mean fluorescent intensity suggested variable diagnostic accuracy across studies. FGS shows great potential in improving IMA, although standardization in methodologies and reporting is needed. Conclusion: This scoping review highlights the potential of intraoperative FGS to enhance treatment accuracy in solid HNC, though variability in diagnostic efficacy and a lack of standardized methodologies persist. Advancements in fluorophore technology and uniform procedural protocols are essential to optimize surgical outcomes and move towards personalized HNC interventions.